This site is no longer being updated. Data are accurate as of 2 Dec 2022.

PT Bio Farma: SARS-CoV-2 Protein Subunit Recombinant Vaccine

PT Bio Farma: SARS-CoV-2 Protein Subunit Recombinant Vaccine

Vaccine Type: Protein Subunit

About Trial Phases

Phase 1: 1 Trial

NCT05067894
Indonesia

Phase 2: 3 Trials

NCT05067894
Indonesia
NCT05313035
Indonesia
NCT05525208
Indonesia

Phase 3: 1 Trial

NCT05313035
Indonesia

Approvals

This vaccine is not yet approved.

Registered Trials

NCT05313035
Phase 2/3
Indonesia
Total Enrollment: 3,960
Official Trial Registration:
- NCT05313035(Opens in new tab/window)
NCT05525208
Phase 2
Indonesia
Total Enrollment: 900
Official Trial Registration:
- NCT05525208(Opens in new tab/window)
NCT05067894
Phase 1/2
Indonesia
Total Enrollment: 780
Official Trial Registration:
- NCT05067894(Opens in new tab/window)

© 2023 VIPER Group COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

This site is provided for informational purposes only based on publically available data.

Site Credits Website Feedback Form